Serum nevirapine and efavirenz concentrations and effect of concomitant rifampicin in HIV infected children on antiretroviral therapy

Indian Pediatrics

Volumn 48, Issue 12, 2011, Pages 943-947

  Shah, Ira ^a   Swaminathan, Soumya ^b   Ramachandran, Geetha ^b   Hemanth Kumar, A K ^b   Goray, Apurva ^a   Chaddha, Udit ^a   Tayal, Swati ^a   Lala, Mamatha ^a  

^a B J WADIA HOSPITAL FOR CHILDREN   (India)

^b NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

Author keywords

Anti retroviral; Drug levels; Efavirenz; Nevirapine; Rifampicin therapy

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; RIFAMPICIN; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MONITORING; DRUG POTENTIATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FUNCTION TEST; MALE; PATIENT MONITORING; TABLET FORMULATION; VIRUS LOAD;

ANTI-HIV AGENTS; BENZOXAZINES; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; HIV INFECTIONS; HUMANS; MALE; NEVIRAPINE; RIFAMPIN;

EID: 84856302613     PISSN: 00196061     EISSN: 09747559     Source Type: Journal    
DOI: 10.1007/s13312-011-0153-3     Document Type: Article

References (25)

1. World Health Organization. Antiretroviral therapy of HIV infection in infants and children. Available on URL: http://www.who.int/hiv/pub/guidelines/ paediatric020907.pdf. Accessed on November 25, 2009.
2. Tréluyer JM. The value of plasma antiretroviral drug monitoring in the management of HIV infected patients. Ann Med Interne (Paris). 2000;151:291-296.
3. Fletcher CV, Fenton T, Powell C, Anderson PL, Brundage RC, Spector SA, et al. Pharmacologic characteristics of efavirenz (EFV) and nelfinavir (NFV) associated with virologic response in HIV-infected children. 8th Conference on Retroviruses and Opportunistic Infections, 2001. Chicago, USA. Abstract 259. Available at: http://www.retroconference.org/2001/abstracts/abstracts/abstracts/ 259.htm. Accessed on November 25, 2009.
4. Burger D, Felderhof M, Phanupak P, Duncombe C, Mahanontharit A, Yeamwanichnunet W, et al. Both shortterm and virological efficacy and drug-associated nephrotoxicity are related to indinavir (IDV) pharmacokinetics (PK) in HIV-1-infected Thai patients. 8th Conference on Retroviruses and Opportunistic Infections, 2001. Chicago, USA. Abstract 730. Available at: http://www.retroconference.org/2001/abstracts/abstracts/abstracts/730.htm. Accessed on November 25, 2009.
5. Anderson PL, Brundage RC, Kakuda TN, Fletcher CV. Indinavir (IDV) maximum plasma concentration (Cmax) predicts CD4+ response in persons with highly suppressed HIV RNA. 8th Conference on Retroviruses and Opportunistic Infections, 2001. Chicago, USA. Abstract 731. Available at: http://www.retroconference.org/ 2001/abstracts/abstracts/abstracts/731.htm. Accessed on November 25, 2009.
6. Clevenbergh P, Durant J, Garraffo R, Kirstetter M, Daures JP, Dellamonica P, et al. Usefulness of protease inhibitor therapeutic drug monitoring? PharmAdapt: a prospective multicentric randomized controlled trial: 12 weeks results. 8th Conference on Retroviruses and Opportunistic Infections, 2001. Chicago, USA. Abstract 260B. Available at: http://www.retroconference.org/2001/ abstracts/abstracts/abstracts/260b.htm. Accessed on November 25, 2009
7. Dahri K, Ensom MH. Efavirenz and nevirapine in HIV-1 infection: is there a role for clinical pharmacokinetic monitoring? Clin Pharmacokinet. 2007;46:109-132. (Pubitemid 46193057)
8. Stohr W, Back D, Dunn D, Sabin C, Winston A, Gilson R, et al. Liverpool TDM Database; UK CHIC Study. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and comedication. Antivir Ther. 2008;13:675-685.
9. King JR, Acosta EP, Chadwick E, Yogev R, Crain M, Pass R, et al. Evaluation of multiple drug therapy in human immunodeficiency virus-infected pediatric patients. Pediatr Infect Dis J. 2003;22:239-244. (Pubitemid 36351072)
10. Ramachandran G, Hemanth Kumar AK, Kumaraswami V, Swaminathan S. Simple liquid chromatography method for simultaneous determination of zidovudine and nevirapine in plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;843:339-344. (Pubitemid 44636429)
11. Ramachandran G, Hemanth Kumar AK, Swaminathan S, Venkatesan P, Kumaraswami V, Greenblatt DJ. Simple and rapid liquid chromatography method for determination of efavirenz in plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;835:131-135.
12. Agarwal DK, Agarwal KN. Physical growth in Indian affluent children (Birth - 6 years). Indian Pediatr. 1994:31:377-413.
13. Agarwal DK, Agarwal KN, Upadhyay SK, Mittal R, Prakash R, Rai S. Physical and sexual growth pattern of affluent children from 6-18 years of age. Indian Pediatr. 1992;29:1203-1282.
14. Mulenga V, Fillekes Q, Kabamba D, Kankasa C, Thomason M, Ferrier A, et al. Pharmacokinetics of nevirapine in 3- to 6-kg, HIV-infected infants taking pediatric fixed-dose combination tablets. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada Feb 8-11, 2009. Abstract 881. http://www.retroconference.org/2009/ Abstracts/34683.htm. Accessed on November 25, 2009.
15. National Aids Control Organization (NACO). Guidelines for HIV Care and Treatment in Infants and Children, 2006. Available at URL: http://www. nacoonline.org/upload/Publication/Treatment%20Care%20and%20support/ Guidelines%20for%20HIV%20care%20and%20treatment%20in%20Infants%20and%20children. pdf. Accessed on November 25, 2009.
16. PENTA guidelines for the use of anti-retroviral therapy in paediatric infection. 2008 Available at URL: http://www.pentatrials.org/guide08.pdf. Accessed on November 25, 2009
17. Cohen K, Gilles van Cutsem, Boulle A, McIlleron H, Goemaere E, Smith P, et al. Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. J Antimicrob Chemother. 2008;61:389-393.
18. Stöhr W, Back D, Dunn D, Sabin C, Winston A, Gilson R, et al. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and comedication. Antivir Ther. 2008;13:675-685.
19. Barlow-Mosha L, Musoke P, Parsons T, Ajuna P, Lutajjumwa M, Musoke B, et al. Nevirapine concentrations in HIV-infected Ugandan children on adult fixed-dose combination tablet ART, with and without rifampicin-based treatment for active M. tuberculosis infection. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada Feb 8-11, 2009. Abstract 909. Available at URL: http://www.retroconference.org/2009/Abstracts/35604.htm. Accessed on November 25, 2009.
20. Ren Y, Nuttall JJ, Eley BS, Meyers TM, Smith PJ, Maartens G, et al. Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr. 2009;50:439-443.
21. Prasitsuebsai W, Cressey T, Capparelli E, Vanprapar N, Lapphra K, Chearskul P, et al. Pharmacokinetics of nevirapine when co administered with rifampicin in HIV infected Thai children with tuberculosis. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada Feb 8-11, 2009. Abstract 908. Available at URL: http://www.retroconference.org/2009/Abstracts/ 34148.-htm. Accessed on November 25, 2009.
22. Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis. 2005;191:825-829. (Pubitemid 40349795)
23. Shah I. Adverse effects of antiretroviral therapy in HIV-1 infected children. J Trop Pediatr. 2006;52:244-248. (Pubitemid 44304886)
24. Alexanian A, Gibbons S, Lyall EGH, Walters S, Khoo S, Tudor-Williams G. Higher nevirapine doses correlate with improved outcomes in a paediatric population. Seventh International Congress on Drug Therapy in HIV infection. Glasgow, UK. 14-18 Nov 2004. Abstract PL11.2. Available at URL: http://www.aegis.com/conferences/hiv-glasgow/2004/PL11-2.html. Accessed on November 25, 2009.
25. Monif T, Rao TN, Tippabhotla SK, Khuroo A, Marwah A, Shrivastav VK, et al. A single-dose, randomized, openlabel, two-period crossover bioequivalence study of a fixed-dose pediatric combination of lamivudine 40 mg, nevirapine 70 mg, and stavudine 10 mg tablet for oral suspension with individual liquid formulations in healthy adult male volunteers. Clin Ther. 2007;29:2677-2684.